Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

This study aimed to prospectively explore severity and prevalence of chemotherapy-induced peripheral neuropathy (CIPN) and examine the correlation between clinician-assessed (objective) and patient-reported (subjective) CIPN in breast cancer survivors receiving taxane.

Methods

This was a prospective, longitudinal study. Purposive sampling was adapted to enroll women newly diagnosed with breast cancer and about to receive taxane. The CIPN was assessed after breast cancer diagnosed and before chemotherapy (T1), before cycle 1 to 4 taxane infusion (T2 to T5), and after chemotherapy completion (T6 to T8). Total Neuropathy Score–clinical version (TNSc), Identification Pain Questionnaire (ID pain), Functional Assessment of Cancer Therapy–Taxane subscale (FACT-Tax), and Peripheral Neuropathy Scale (PNS) were utilized for measuring CIPN. Descriptive statistics, Pearson correlation coefficient, and generalized estimating equation were used to analyze data.

Results

A total of 88 participants were included. Both clinician-assessed and patient-reported CIPN gradually increased between T1 and T6 and mildly decreased at T7 and T8. Fifty-five participants (62.5%) experienced CIPN at T8. Weak-to-moderate correlations between subjective and objective CIPN were found at T6 to T8 (r = 0.272–0.533, p < 0.05). The change of TNSc, FACT-Tax, and PNS were significant over time. However, the significant change of neuropathic pain was only found at T6.

Conclusion

The change of CIPN prevalence and severity were significant over time in survivors newly diagnosed with breast cancer. Specifically, the severest and highest CIPN was detected at chemotherapy completion. Survivors remained suffering from CIPN 3 months after chemotherapy completion. Besides, mild to moderate correlations between clinician-assessed and patient-reported CIPN were identified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Availability of data and material

Ya-Jung Wang keeps research data and material.

References

  1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590

  2. Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2016) SEER Cancer statistics review 1975-2016, National Cancer Institute. eds; Available from: https://seer.cancer.gov/csr/1975_2016/. Accessed 21 February 2020

  3. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 4. https://doi.org/10.1002/14651858.CD004421.pub2

  4. Ghersi D, Willson ML, Chan MMK, Simes J, Donoghue E, Wilcken N (2015) Taxane-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 6. https://doi.org/10.1002/14651858.CD003366.pub3

  5. Flatters SJL, Dougherty PM, Colvin LA (2017) Clinical and preclinical perspectives on chemotherapy-induced peripheral neuropathy (CIPN): a narrative review. Br J Anaesth 119(4):737–749. https://doi.org/10.1093/bja/aex229

  6. Velasco RJ, Bruna J (2015) Taxane-induced peripheral neurotoxicity. Toxics 3(2):152–169. https://doi.org/10.3390/toxics3020152

  7. Hong JS, Tian J, Wu LH (2014) The influence of chemotherapy-induced neurotoxicity on psychological distress and sleep disturbance in cancer patients. Curr Oncol 21(4):174–180. https://doi.org/10.3747/co.21.1984

  8. Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ, Bao T (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333. https://doi.org/10.1007/s10549-016-3939-0

  9. Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, Hopkins J, Tejani M, Morrow GR, Mohile S (2013) Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer 21(7):2059–2066. https://doi.org/10.1007/s00520-013-1766-y

  10. Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261–2269. https://doi.org/10.1007/s00520-014-2255-7

  11. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020

  12. Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J (2018) Chemotherapy-associated peripheral neuropathy in patients with early-stage breast cancer: a systematic review. J Natl Cancer I 110(2). https://doi.org/10.1093/jnci/djx140

  13. Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 3:366. https://doi.org/10.1186/2193-1801-3-366

  14. Loprinzi CL, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz DL, Kelley MR, Lavino A, Lustberg MB, Paice JA, Schneider BP (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. J Clin Oncol: JCO. 20.01399. https://doi.org/10.1200/JCO.2013.54.0914

  15. Donovan HS, Campbell GB (2018) Persistent chemotherapy-induced peripheral neuropathy: are dose reductions and drug modifications our only options? Gynecol Oncol 149(3):433–434. https://doi.org/10.1186/2193-1801-3-366

  16. Beijers AJ, Beijers AJ, Mols F, Van den Hurk CJ, Vreugdenhil A (2016) Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria. Aata Oncol 55(4):516–518. https://doi.org/10.3109/0284186X.2015.1073352

  17. Salgado TM, Quinn CS, Krumbach EK, Wenceslao I, Gonzalez M, Reed HL, Syverson JG, Etz RS, Vangipuram K, Barker MR, Henry NL, Farris KB, Hertz DL (2020) Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study. Support Care Cancer:1–10. https://doi.org/10.1007/s00520-019-05254-6

  18. Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25(1):257–264. https://doi.org/10.1093/annonc/mdt409

  19. Molassiotis A, Cheng HL, Lopez V, Au JS, Chan A, Bandla A, Leung KT, Li YC, Suen LKP, Chan CW, York J, Farrel C, Sundar R (2019) Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 19(1):132. https://doi.org/10.1186/s12885-019-5302-4

  20. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer 20(12):3355–3364. https://doi.org/10.1007/s00520-012-1492-x

  21. Kuroi K, Shimozuma K, Ohashi Y, Hisamatsu K, Masuda N, Takeuchi A, Aranishi T, Morita S, Ohsumi S, Hausheer FH (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 17(8):1071–1180. https://doi.org/10.1007/s00520-008-0550-x

  22. Faul F, Erdfelder E, Buchner A, Lang AG (2009) Statistical power analyses using G* Power 3.1: Tests for correlation and regression analyses. Behav Res Methods 41(4):1149–1160

  23. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology. Cancer 98(4):822–831. https://doi.org/10.1002/cncr.11578

  24. Almadrones L, McGuire DB, Walczak JR, Florio CM, Tian C (2004) Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum 31(3):615–623. https://doi.org/10.1188/04.ONF.615-623

  25. Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua GE, Manicone M, Giussani G (2006) Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 11(2):135–141. https://doi.org/10.1111/j.1085-9489.2006.00078.x

  26. Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Frigeni B, Alberti VR, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dall Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24(2):454–462. https://doi.org/10.1093/annonc/mds329

  27. Chan A, Wong S, Chen PP, Tsoi TH, Lam J, Ip WY, Wong CP, Wong L, Mok V (2011) Validation study of the Chinese identification pain questionnaire for neuropathic pain. Hong Kong Med J 17(4):297–300

  28. Portenoy R, Pain Steering Committee ID (2006) Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr Med Res Opin 22(8):1555–1565. https://doi.org/10.1185/030079906X115702

  29. Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA (2019) Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer 125(17):2945–2954. https://doi.org/10.1002/cncr.32175

  30. Song SJ, Min J, Suh SY, Jung SH, Hahn HJ, Im SA, Lee JY (2017) Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast cancer. Support Care Cancer 25(7):2241–2248. https://doi.org/10.1007/s00520-017-3631-x

  31. Monfort SM, Monfort SM, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, Loprinzi CL, Chaudhari AMW, Lustberg MB (2017) Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. Breast Cancer Res Treat 164(1):69–77. https://doi.org/10.1007/s10549-017-4230-8

  32. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, Awad D, Crew KD (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774. https://doi.org/10.1007/s10549-010-1278-0

  33. McCrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Friedlander M, Bosco A, Harrison M, Maier N, O'Neill S, Park SB (2019) Optimizing clinical screening for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manag 58(6):1023–1032. https://doi.org/10.1016/j.jpainsymman.2019.07.021

  34. Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TRD, Suen LKP, Chan CW, Yorke J, Lopez V (2019) Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane-and platinum-based chemotherapy. Brain Behav 9(6):e01312. https://doi.org/10.1002/brb3.1312

  35. Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA (2018) Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst 110(2):djx162. https://doi.org/10.1093/jnci/djx162

  36. Bayo J, Prieto B, Rivera F (2016) Comparison of doctors’ and breast cancer patients’ perceptions of docetaxel, epirubicin, and cyclophosphamide (TEC) toxicity. Breast J 22(3):293–302. https://doi.org/10.1111/tbj.12571

  37. Kanzawa-Lee GA, Knoerl R, Donohoe C, Bridges CM, Smith EML (2019) Mechanisms, predictors, and challenges in assessing and managing painful chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 35(3):253–260. https://doi.org/10.1016/j.soncn.2019.04.006

  38. Park SB, Alberti P, Kolb NA, Gewandter JS, Schenone A, Argyriou AA (2019) Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 24:S13–S25. https://doi.org/10.1111/jns.12333

  39. Ventzel L, Jensen AB, Jensen AR, Jensen TS, Finneru NB (2016) Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel. Pain 157(3):560–568. https://doi.org/10.1097/j.pain.0000000000000404

  40. Ramnarine S, Rolke R, Colvin LA, Fallon MT (2018) Investigating nerve fibre damage in chemotherapy-induced peripheral neuropathy (CIPN): a prospective study. J Clin Oncol 36(15s):e22096. https://doi.org/10.1200/JCO.2018.36.15_suppl.e22096

  41. Reyes-Gibby CC, Morrow PK, Buzdar A, Shete S (2009) Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel. J Pain 10(11):1146–1150. https://doi.org/10.1016/j.jpain.2009.04.006

  42. Timmins HC, Li T, Kiernan MC, Baron-Hay S, Marx G, Boyle F, Goldstein D, Park SB (2020) Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Support Care Cancer 11:1–8. https://doi.org/10.1007/s00520-020-05299-y

  43. Curcio KR (2016) Instruments for assessing chemotherapy-induced peripheral neuropathy: a review of the literature. Clin J Oncol Nurs 20(2):144–151. https://doi.org/10.1188/16.CJON.20-01AP

  44. Smith EM, Knoerl R, Yang JJ, Kanzawa-Lee G, Lee D, Bridges CM (2018) In search of a gold standard patient-reported outcome measure for use in chemotherapy-induced peripheral neuropathy clinical trials. Cancer Control 25(1):1073274818756608. https://doi.org/10.1177/1073274818756608

  45. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG, the CI-PeriNomS Group (2019) Patients’ and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 24(1):111–119. https://doi.org/10.1111/jns.12306

  46. Tan AC, McCrary JM, Park SB, Trinh T, Goldstein D (2019) Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade. Support Care Cancer 27(12):4771–4777

Download references

Funding

Authors would like to acknowledge the funding support by the Ministry of Science Technology, R.O.C. (MOST 104-2314-B-010-064-).

Author information

Authors and Affiliations

  1. Department of Nursing, DaYeh University, 168, University Rd., Dacun, Changhua, 51591, Taiwan

    Ya-Jung Wang

  2. School of Nursing, University of North Carolina at Chapel Hill, 120 N. Medical Dr. Carrington Hall#CB 7460, Chapel Hill, NC, 27599-7460, USA

    Ya-Ning Chan

  3. Department of Nursing, Taichung Veterans General Hospital, 1650 Taiwan Boulevard Sect. 4, Taichung, 40705, Taiwan

    You-Wun Jheng

  4. Department of Nursing, National Yang-Ming University, 155, Sec. 2, Li-Nong St., Beitou Dist, Taipei, 11221, Taiwan

    Ya-Jung Wang & Chih-Jung Wu

  5. Institute of Public Health, National Yang-Ming University, 155, Sec. 2, Li-Nong St., Beitou Dist, Taipei, 11221, Taiwan

    Ming-Wei Lin

  6. Department of Surgery, Veterans General Hospital-Taipei, 201, Sec. 2, Shih, Pai Rd., Taipei, 11217, Taiwan

    Ling-Ming Tseng & Yi-Fang Tsai

  7. Department of Breast Surgery, China Medical University Hospital, 2, Yude Road, North District, Taichung City, 404472, Taiwan

    Liang-Chih Liu

Authors
  1. Ya-Jung Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ya-Ning Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. You-Wun Jheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chih-Jung Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming-Wei Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ling-Ming Tseng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi-Fang Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Liang-Chih Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization and supervision: Ya-Jung Wang

Methodology: Ya-Jung Wang and Ming-Wei Lin

Formal analysis and investigation: Ya-Jung Wang, Ming-Wei Lin, Ya-Ning Chan, You-Wun Jheng, Chih-Jung Wu, Ling-Ming Tseng, Yi-Fang Tsai, and Liang-Chih Liu

Writing-original draft preparation, review, and editing: Ya-Jung Wang, Ya-Ning Chan, and Ming-Wei Lin Funding acquisition and resources: Ya-Jung Wang, Ming-Wei Lin, Ling-Ming Tseng, Yi-Fang Tsai, and Liang-Chih Liu

Corresponding author

Correspondence to Ya-Jung Wang.

Ethics declarations

Conflicts of interest

All authors declare that they have no conflict of interest.

Ethics approval

The questionnaire and methodology for current study was approved by the Human Research Ethics committee of the National Yang Ming University (Ethics approval number: YM104066E-1), the Taipei Veteran General Hospital (Ethics approval number: 2015-09-003CC), and the China Medical University Hospital (Ethics approval number: CMUH104-REC1-127).

Consent to participate

Written informed consent was obtained from all individual participants included in current study.

Consent for publication

Participants signed informed consent regarding publishing their data.

Author’s confidentiality

All authors treat all communications with the Journal as confidential.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, YJ., Chan, YN., Jheng, YW. et al. Chemotherapy-induced peripheral neuropathy in newly diagnosed breast cancer survivors treated with taxane: a prospective longitudinal study. Support Care Cancer 29, 2959–2971 (2021). https://doi.org/10.1007/s00520-020-05796-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-020-05796-0

Keywords

Search

Navigation